Valid Therapeutics
Valid Therapeutics is a Massachusetts TechBio company that combines hiPSC-derived co-culture disease models, automated high-throughput screening, and a multimodal AI engine (Lab-in-the-Loop) to deliver predictive human biology data for global pharmaceutical drug discovery partners.
- Company typePrivate
- Founded2024
- HeadquartersNatick, United States
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What Valid Therapeutics does
Valid Therapeutics is a Massachusetts-based TechBio company founded in 2024 that operates a drug discovery platform combining human induced pluripotent stem cell (hiPSC)-derived co-culture disease models, automated high-throughput perturbation screening, and a multimodal measurement pipeline (imaging, RNA-seq, proteomics) feeding a Lab-in-the-Loop AI engine. The platform is designed to convert phenotypic human biology into AI-ready data to improve predictive validity in early-stage drug discovery, targeting global pharmaceutical and biotechnology companies seeking to reduce late-stage clinical attrition. Programs span neuronal co-cultures for neurodegeneration to peripheral models covering muscle, adipose, and liver tissues for metabolic disease.
The company is led by co-founders Tim Ahfeldt (CEO, formerly of Harvard, Mount Sinai, and Recursion) and Josh Lamstein (CFO/COO, PE and operations background), with Ole Wiskow heading platform operations, Rob Moccia heading AI and data, and a scientific advisor roster that includes Andreas Bender, Berton Earnshaw, Jack Scannell, Lee Rubin, Rafi Hofstein, and Yael Weiss. The technical differentiator is the integration of fragile hiPSC co-culture biology with industrial-grade laboratory automation (384/1536-well formats), an unusually cross-functional stack that the company positions as a self-optimizing discovery engine rather than a static assay provider.
Commercially, Valid operates an enterprise field-sales motion targeting global pharma through direct partnerships and collaborations, with revenue expected to flow from research collaborations and platform access contracts. The company is privately held, raised approximately $6.86M in a single funding round in January 2025, and has roughly 20 listed personnel across leadership, scientific staff, and advisors based in Wayland and Natick, Massachusetts.
Valid Therapeutics firmographics
Firmographics- Name
- Valid Therapeutics
- Legal name
- Valid, Inc.
- Website
- https://validtx.com
- Company type
- Private
- Founded year
- 2024
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Valid Therapeutics is a Massachusetts TechBio company that combines hiPSC-derived co-culture disease models, automated high-throughput screening, and a multimodal AI engine (Lab-in-the-Loop) to deliver predictive human biology data for global pharmaceutical drug discovery partners.
- Ownership category
- akta.pro rank
Valid Therapeutics industry classification
Industry- Product category
- Drug Discovery Platform
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
- akta.pro secondary industries
- AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE), Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI), Translational Medicine & Biomarkers (HLAIALAF)
Keywords
Where Valid Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Natick
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Valid Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
Revenue model
- Pharma Partnerships and Collaborations: VALID generates revenue through strategic partnerships with global pharmaceutical companies. The platform is used to identify targets and hits, validate leads, and improve the drug discovery funnel. Partnerships likely involve research collaborations, licensing of platform capabilities, and potentially milestone-based payments.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
Valid Therapeutics product offering
Product offeringCore offering
Valid Therapeutics operates a TechBio platform that combines human iPSC-derived co-culture disease models with automated high-throughput perturbation screening and AI-driven multimodal measurement (imaging, RNA-seq, proteomics) to predict drug efficacy for global pharmaceutical partners. The platform's Lab-in-the-Loop Engine uses experimental biology to validate AI hypotheses in a continuous refinement loop, enabling earlier and more predictive identification of targets, hits, leads, and drug candidates.
Product overview
VALID Therapeutics offers a unified TechBio platform called the VALID Platform for predictive human biology at scale. The core offering integrates human iPSC-derived co-culture disease models, automated high-throughput perturbation screening, and a multimodal measurement pipeline (capturing imaging, transcriptomics, and proteomics). A key component is the Lab-in-the-Loop Engine, which creates a continuous loop where experimental biology validates AI predictions, which in turn generates better hypotheses for experimental validation. The platform spans multiple human systems including neuronal co-cultures for neurodegeneration and peripheral models for metabolic disease, with each dataset compounding knowledge to fuel continuous predictive discovery.
Differentiator
Problem solved
Functional benefit
Products and services
- VALID Platform An integrated TechBio platform for predictive human biology at scale that combines human iPSC-derived co-culture disease models, automated 384- and 1536-well perturbation screening, and multimodal measurement (imaging, transcriptomics, proteomics) to convert phenotypic biology into AI-ready data. Built for global pharmaceutical companies seeking earlier efficacy testing, improved target and lead validation, and reduced late-stage clinical trial failures across neurodegeneration and metabolic disease programs.
Quantifiable outcome
- Reduced late-stage clinical trial failures by improving predictive validity of preclinical models
Companies that use Valid Therapeutics
Customer profileSegments1 record
Ideal customer profiles1 record
Valid Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability6 records
Feature4 records
Valid Therapeutics partnerships and signals
Strategic signalScale indicators1 record
Recent moves5 records
Expansion highlights5 records
Valid Therapeutics competitors and assessment
Company assessmentBroad incumbents
- Schrödinger: Established computational chemistry and biology platform serving pharma with physics-based modeling plus ML. Overlaps with Valid in AI-driven pharma drug discovery but is anchored in computational chemistry rather than wet-lab hiPSC biology.
- CytoReason: AI company building cell-level computational models of disease for pharma R&D. Comparable in providing AI-driven disease models to pharma partners, though using bulk and single-cell omics rather than hiPSC perturbation data.
- Ginkgo Bioworks: Large-scale cell engineering and biosecurity platform offering automated, high-throughput biological experimentation as a service to partners. Overlaps in the automated biology-as-a-service thesis, though focused on synthetic biology rather than therapeutic discovery.
Direct peers
- Verge Genomics: AI-driven drug discovery company focused on neurodegenerative diseases using human patient-derived data and disease models. Comparable target indication (neurodegeneration) and platform-based discovery model.
- Insitro: ML-enabled drug discovery company using iPSC-derived cell models and high-throughput biology to build predictive models of disease. Directly comparable in the hiPSC-plus-AI thesis and in pharma partnership GTM motion.
- Recursion Pharmaceuticals: TechBio company combining high-throughput biology with AI/ML for drug discovery. CEO Ahfeldt previously worked at Recursion, and both companies target phenotypic screening plus predictive modeling, though Recursion operates at far larger scale with phenomics and an internal pipeline.
Emerging players
- Owkin: AI-biotech company applying machine learning to patient-derived data for drug discovery and clinical development with pharma partners. Comparable GTM to pharma and ML-driven biology positioning, though more patient-data focused than hiPSC.
- Spring Discovery: AI-driven drug discovery company developing therapies for aging-related diseases. Comparable in the small TechBio peer set pursuing biology + AI approaches with pharma partnerships.
- BioAge Labs: AI-driven biotech targeting aging and metabolic disease, using machine learning on human data to identify drug targets. Overlaps with Valid's metabolic and aging-related disease programs.
- Phenomic AI: Uses single-cell RNA-seq and AI to identify drug targets in disease-relevant cell types. Adjacent to Valid in the AI-on-biology thesis but operates at smaller scale and without the hiPSC automation stack.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
Valid Therapeutics social profiles
Digital presenceValid Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Valid Therapeutics leadership team
Management profileNumber of profiles
Profiles5 records
Valid Therapeutics funding detail
Funding detailFunding overview
Funding rounds1 record
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Valid Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Valid Therapeutics
What does Valid Therapeutics do?
Valid Therapeutics operates a TechBio platform that combines human iPSC-derived co-culture disease models with automated high-throughput perturbation screening and AI-driven multimodal measurement (imaging, RNA-seq, proteomics) to predict drug efficacy for global pharmaceutical partners. The platform's Lab-in-the-Loop Engine uses experimental biology to validate AI hypotheses in a continuous refinement loop, enabling earlier and more predictive identification of targets, hits, leads, and drug candidates.
Is Valid Therapeutics a public or private company?
Valid Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.
When was Valid Therapeutics founded?
Valid Therapeutics was founded in 2024. It employs 11 to 50 people.
Where is Valid Therapeutics based?
Valid Therapeutics is headquartered in Natick, United States, in the North America region.
How does Valid Therapeutics make money?
One revenue line is on record: pharma Partnerships and Collaborations.
Who are Valid Therapeutics's main competitors?
Broad incumbents on record are Schrödinger, CytoReason and Ginkgo Bioworks. Direct peers are Verge Genomics, Insitro and Recursion Pharmaceuticals. Emerging players are Owkin, Spring Discovery, BioAge Labs and Phenomic AI.
Does Valid Therapeutics have an API?
No public API is recorded for Valid Therapeutics.
What industry is Valid Therapeutics in?
Valid Therapeutics's product category is Drug Discovery Platform. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening). Its NAICS code is 541714 and its SIC code is 8731.